Alpha cognition secures additional u.s. patent for zunveyl (benzgalantamine) in the treatment of mild to moderate alzheimer's disease

Vancouver--(business wire)--alpha cognition inc. (nasdaq: acog) (“alpha cognition” (aci), or the “company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the united states patent and trademark office (uspto) has granted a new patent titled “coated tablets for ph-dependent release of benzgalantamine.” this newly issued patent strengthens alpha cognition's intellectual property portfolio by covering the composition of.
ACOG Ratings Summary
ACOG Quant Ranking